Clinical Trial Detail

NCT ID NCT02263898
Title Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Jonsson Comprehensive Cancer Center
Indications

melanoma

Therapies

Binimetinib + Encorafenib

Age Groups: adult

Additional content available in CKB BOOST